From: Mesenchymal stem cells for cartilage repair in osteoarthritis
Study number | Authors or institution | Number of subjects | Type of study | Cell type and dose used | Efficacy parameters | Outcome | Duration offollow-up | Referenceor Clinical-Trials. govidentifier |
---|---|---|---|---|---|---|---|---|
1 | Kuroda et al., 2007 [40] | 1 | Case report | Autologous BM-MSCs + collagen gel | Arthroscopy and HPE | Defect filled with hyaline-like type of cartilage tissue | 1 year | [40] |
2 | Wakitani et al., 2007 [41] | 3 | Case series | Autologous BM-MSCs (5 million) + collagen sheet | HPE and MRI | Histology: defect repaired with fibrocartilaginous tissue MRI: complete coverage of defect | 1 year | [41] |
3 | Osiris Therapeutics, Inc. (Columbia, MD, USA), 2007 | 55 | Randomized double-blind | Allogeneic BM-MSCs (50 and 150 million) | VAS pain score and MRI | VAS: Significantly reduced pain MRI: Decreased degenerative bone changes | 2 years | |
4 | Centeno et al., 2008 [45] | 1 | IRB-approved study | Autologous BM-MSCs (22.4 million) + 1 mL of nucleated cells + 1 mL of 10% platelets | VAS pain score and MRI knee joint | Decreased VAS score MRI: increase in meniscus and femoral cartilage volume | 24 weeks | [45] |
5 | Nejadnik et al., 2010 [39] | 72 | Observational cohort study | Autologous BM-MSCs: n = 36; Chondrocytes: n = 36 | ICRS Cartilage Injury Evaluation Package | Improvement in physical role functioning in BM-MSCs | 2 years | [39] |
6 | Davatchi et al., 2011 [44] | 4 | IRB-approved study | Autologous BM-MSCs (8 to 9 million) | Walking time for the pain to appear and VAS pain score | Walking time for pain improved in 3 patients VAS decreased in all patients | 1 year | [44] |
7 | Haleem et al., 2012 [42] | 5 | Case series | Autogous BMSCs placed on platelet-rich fibrin glue | RHSSK scores and MRI | Improvement in RHSSK score and subjective symptoms MRI: complete defect fill and complete surface congruity with native cartilage | 1 year | [42] |
8 | Kasemkijwattana et al., 2011 [43] | 2 | Case report | Autologous BMSCs (12 million) | KOOS, IKDC score, and arthroscopy | Improvements in KOOS and IKDC score Arthroscopy: Good defect fill, stiffness, and incorporation to the adjacent cartilage | 30-31 months | [43] |
9 | National University of Malaysia/ Cytopeutics (Malaysia) | 50 | Randomized controlled | Autologous BMSCs | VAS, IKDC Subjective Knee Evaluation Form, and x-ray | NA | 1 year | NCT01459640 |
10 | Royan Institute (Tehran, Iran) | 40 | Randomized triple-blinded | Autologous BMSCs | WOMAC, VAS, and MRI | NA | 6 months | NCT01504464 |
11 | Red de Terapia Celular (Barcelona, Spain) | 12 | Non- randomized open-label | Autologous BMSCs (40 million) | VAS, Oswestry disability index, and SF-36 life quality | NA | 2 years | NCT01183728 |
12 | Royan Institute | 6 | Non-randomized open-label | BMSCs | WOMAC, VAS, SF-36, and MRI | NA | 1 year | NCT01207661 |
13 | Royan Institute | 6 | Non-randomized open-label | Autologous BMSCs | VAS, WOMAC, x-ray, and MRI | NA | 6 months | NCT01436058 |
14 | Royan Institute | 6 | Non-randomized open-label | Autologous BMSCs | VAS, WOMAC, Harris Hip Score questionnaire, x- ray, and MRI | NA | 6 months | NCT01500811 |
15 | Stempeutics Research (Bangalore, India) | 60 | Randomized double-blind | Allogeneic BMSCs (25, 50, 75, and 150 million) | VAS, WOMAC, ICOAP, x-ray, and MRI | NA | 2 years | NCT01453738 |
16 | University of Marseille (Marseille, France) | 50 | Open-label | Autologous BMSCs | IKS and ICRS | NA | 1 year | NCT01159899 |
17 | Stempeutics Research Malaysia Sdn. Bhd (Malaysia) | 72 | Randomized double-blind | Allogeneic BMSCs (25 and 50 million) | VAS, WOMAC, ICOAP, x-ray, and MRI | NA | 2 years | NCT01448434 |
18 | Cairo University (Egypt) | 25 | Open-label | Autologous BMSCs | Clinical scoring, x-ray, and MRI | NA | 1 year | NCT00891501 |
19 | Royan Institute | 6 | Open-label | Autologous BMSCs | Pain, knee cartilage defects | NA | 1 year | NCT00850187 |
20 | Banc de Sang i Teixits (Barcelona, Spain) | 15 | Open-label | Autologous BMSCs (40 million) | VAS, HAQ, SF-36, and MRI | NA | 1 year | NCT01227694 |
21 | Mesoblast (Melbourne, Australia) | 24 | Randomized double-blind | MSB-CAR001 | VAS, KOOS, SF-36, x-ray, and MRI | NA | 2 years | NCT01088191 |